http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 17 Jun 2026 01:15:53 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Eisai+invests+%C2%A348M+in+UK+manufacturing+with+government+backing/26655902.html <p>Eisai Co., Ltd. (Tokyo Stock Exchange: 4523) announced a strategic investment of approximately £48 million at its manufacturing site in Hatfield, Hertfordshire, United Kingdom, supported by the UK Government's Life Sciences Innovative Manufacturing Fund (LSIMF).</p> <p>The investment is intended to establish supply chain and packaging capabilities for medicines requiring cold-chain management, including lecanemab, an Alzheimer's treatment. The project will expand the Hatfield site's role beyond traditional oral solid dose operations to include packaging and supply of temperature-controlled medicines for injection and infusion.</p> <p>LSIMF is a capital grants scheme designed to strengthen life sciences manufacturing in the UK and improve supply resilience. The http://www.streetinsider.com/Corporate+News/Eisai+invests+%C2%A348M+in+UK+manufacturing+with+government+backing/26655902.html Wed, 17 Jun 2026 01:15:53 -0400 4523 A.50201142 ESAIY ESALF O.04940429 O.05105698 http://www.streetinsider.com/Corporate+News/Eisai+invests+%C2%A348M+in+UK+manufacturing+with+government+backing/26655902.html <p>Eisai Co., Ltd. (Tokyo Stock Exchange: 4523) announced a strategic investment of approximately £48 million at its manufacturing site in Hatfield, Hertfordshire, United Kingdom, supported by the UK Government's Life Sciences Innovative Manufacturing Fund (LSIMF).</p> <p>The investment is intended to establish supply chain and packaging capabilities for medicines requiring cold-chain management, including lecanemab, an Alzheimer's treatment. The project will expand the Hatfield site's role beyond traditional oral solid dose operations to include packaging and supply of temperature-controlled medicines for injection and infusion.</p> <p>LSIMF is a capital grants scheme designed to strengthen life sciences manufacturing in the UK and improve supply resilience. The http://www.streetinsider.com/Corporate+News/Eisai+invests+%C2%A348M+in+UK+manufacturing+with+government+backing/26655902.html Wed, 17 Jun 2026 01:15:53 -0400 4523 A.50201142 ESAIY ESALF O.04940429 O.05105698 http://www.streetinsider.com/Corporate+News/Eisai+invests+%C2%A348M+in+UK+manufacturing+with+government+backing/26655902.html <p>Eisai Co., Ltd. (Tokyo Stock Exchange: 4523) announced a strategic investment of approximately £48 million at its manufacturing site in Hatfield, Hertfordshire, United Kingdom, supported by the UK Government's Life Sciences Innovative Manufacturing Fund (LSIMF).</p> <p>The investment is intended to establish supply chain and packaging capabilities for medicines requiring cold-chain management, including lecanemab, an Alzheimer's treatment. The project will expand the Hatfield site's role beyond traditional oral solid dose operations to include packaging and supply of temperature-controlled medicines for injection and infusion.</p> <p>LSIMF is a capital grants scheme designed to strengthen life sciences manufacturing in the UK and improve supply resilience. The http://www.streetinsider.com/Corporate+News/Eisai+invests+%C2%A348M+in+UK+manufacturing+with+government+backing/26655902.html Wed, 17 Jun 2026 01:15:53 -0400 4523 A.50201142 ESAIY ESALF O.04940429 O.05105698 http://www.streetinsider.com/Corporate+News/Eisai+invests+%C2%A348M+in+UK+manufacturing+with+government+backing/26655902.html <p>Eisai Co., Ltd. (Tokyo Stock Exchange: 4523) announced a strategic investment of approximately £48 million at its manufacturing site in Hatfield, Hertfordshire, United Kingdom, supported by the UK Government's Life Sciences Innovative Manufacturing Fund (LSIMF).</p> <p>The investment is intended to establish supply chain and packaging capabilities for medicines requiring cold-chain management, including lecanemab, an Alzheimer's treatment. The project will expand the Hatfield site's role beyond traditional oral solid dose operations to include packaging and supply of temperature-controlled medicines for injection and infusion.</p> <p>LSIMF is a capital grants scheme designed to strengthen life sciences manufacturing in the UK and improve supply resilience. The http://www.streetinsider.com/Corporate+News/Eisai+invests+%C2%A348M+in+UK+manufacturing+with+government+backing/26655902.html Wed, 17 Jun 2026 01:15:53 -0400 4523 A.50201142 ESAIY ESALF O.04940429 O.05105698 http://www.streetinsider.com/Corporate+News/Eisai+invests+%C2%A348M+in+UK+manufacturing+with+government+backing/26655902.html <p>Eisai Co., Ltd. (Tokyo Stock Exchange: 4523) announced a strategic investment of approximately £48 million at its manufacturing site in Hatfield, Hertfordshire, United Kingdom, supported by the UK Government's Life Sciences Innovative Manufacturing Fund (LSIMF).</p> <p>The investment is intended to establish supply chain and packaging capabilities for medicines requiring cold-chain management, including lecanemab, an Alzheimer's treatment. The project will expand the Hatfield site's role beyond traditional oral solid dose operations to include packaging and supply of temperature-controlled medicines for injection and infusion.</p> <p>LSIMF is a capital grants scheme designed to strengthen life sciences manufacturing in the UK and improve supply resilience. The http://www.streetinsider.com/Corporate+News/Eisai+invests+%C2%A348M+in+UK+manufacturing+with+government+backing/26655902.html Wed, 17 Jun 2026 01:15:53 -0400 4523 A.50201142 ESAIY ESALF O.04940429 O.05105698 http://www.streetinsider.com/Corporate+News/Eisai+invests+%C2%A348M+in+UK+manufacturing+with+government+backing/26655902.html <p>Eisai Co., Ltd. (Tokyo Stock Exchange: 4523) announced a strategic investment of approximately £48 million at its manufacturing site in Hatfield, Hertfordshire, United Kingdom, supported by the UK Government's Life Sciences Innovative Manufacturing Fund (LSIMF).</p> <p>The investment is intended to establish supply chain and packaging capabilities for medicines requiring cold-chain management, including lecanemab, an Alzheimer's treatment. The project will expand the Hatfield site's role beyond traditional oral solid dose operations to include packaging and supply of temperature-controlled medicines for injection and infusion.</p> <p>LSIMF is a capital grants scheme designed to strengthen life sciences manufacturing in the UK and improve supply resilience. The http://www.streetinsider.com/Corporate+News/Eisai+invests+%C2%A348M+in+UK+manufacturing+with+government+backing/26655902.html Wed, 17 Jun 2026 01:15:53 -0400 4523 A.50201142 ESAIY ESALF O.04940429 O.05105698 http://www.streetinsider.com/Press+Releases/Eisai+Announces+Strategic+Investment+Supported+by+the+UK+Government%26apos%3Bs+LSIMF/26655901.html <p>TOKYO, Jun 17, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) today announced a strategic investment supported by the UK Government under the Life Sciences Innovative Manufacturing Fund (LSIMF), subject to terms and conditions, at its manufacturing site in Hatfield, Hertfordshire, United Kingdom, to establish supply chain and packaging capabilities for current and future medicines that require cold-chain management, including lecanemab.</p><p>LSIMF is a capital grants scheme designed to strengthen life sciences manufacturing capabilities in the UK and enhance supply resilience against future health emergencies. The investment aligns with the UK Government&apos;s policy http://www.streetinsider.com/Press+Releases/Eisai+Announces+Strategic+Investment+Supported+by+the+UK+Government%26apos%3Bs+LSIMF/26655901.html Tue, 16 Jun 2026 23:28:00 -0400 4523 A.50201142 ESAIY ESALF O.04940429 O.05105698 http://www.streetinsider.com/Press+Releases/Eisai+Announces+Strategic+Investment+Supported+by+the+UK+Government%26apos%3Bs+LSIMF/26655901.html <p>TOKYO, Jun 17, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) today announced a strategic investment supported by the UK Government under the Life Sciences Innovative Manufacturing Fund (LSIMF), subject to terms and conditions, at its manufacturing site in Hatfield, Hertfordshire, United Kingdom, to establish supply chain and packaging capabilities for current and future medicines that require cold-chain management, including lecanemab.</p><p>LSIMF is a capital grants scheme designed to strengthen life sciences manufacturing capabilities in the UK and enhance supply resilience against future health emergencies. The investment aligns with the UK Government&apos;s policy http://www.streetinsider.com/Press+Releases/Eisai+Announces+Strategic+Investment+Supported+by+the+UK+Government%26apos%3Bs+LSIMF/26655901.html Tue, 16 Jun 2026 23:28:00 -0400 4523 A.50201142 ESAIY ESALF O.04940429 O.05105698 http://www.streetinsider.com/Press+Releases/Eisai+Announces+Strategic+Investment+Supported+by+the+UK+Government%26apos%3Bs+LSIMF/26655901.html <p>TOKYO, Jun 17, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) today announced a strategic investment supported by the UK Government under the Life Sciences Innovative Manufacturing Fund (LSIMF), subject to terms and conditions, at its manufacturing site in Hatfield, Hertfordshire, United Kingdom, to establish supply chain and packaging capabilities for current and future medicines that require cold-chain management, including lecanemab.</p><p>LSIMF is a capital grants scheme designed to strengthen life sciences manufacturing capabilities in the UK and enhance supply resilience against future health emergencies. The investment aligns with the UK Government&apos;s policy http://www.streetinsider.com/Press+Releases/Eisai+Announces+Strategic+Investment+Supported+by+the+UK+Government%26apos%3Bs+LSIMF/26655901.html Tue, 16 Jun 2026 23:28:00 -0400 4523 A.50201142 ESAIY ESALF O.04940429 O.05105698 http://www.streetinsider.com/Press+Releases/Eisai+Announces+Strategic+Investment+Supported+by+the+UK+Government%26apos%3Bs+LSIMF/26655901.html <p>TOKYO, Jun 17, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) today announced a strategic investment supported by the UK Government under the Life Sciences Innovative Manufacturing Fund (LSIMF), subject to terms and conditions, at its manufacturing site in Hatfield, Hertfordshire, United Kingdom, to establish supply chain and packaging capabilities for current and future medicines that require cold-chain management, including lecanemab.</p><p>LSIMF is a capital grants scheme designed to strengthen life sciences manufacturing capabilities in the UK and enhance supply resilience against future health emergencies. The investment aligns with the UK Government&apos;s policy http://www.streetinsider.com/Press+Releases/Eisai+Announces+Strategic+Investment+Supported+by+the+UK+Government%26apos%3Bs+LSIMF/26655901.html Tue, 16 Jun 2026 23:28:00 -0400 4523 A.50201142 ESAIY ESALF O.04940429 O.05105698 http://www.streetinsider.com/Press+Releases/Eisai+Announces+Strategic+Investment+Supported+by+the+UK+Government%26apos%3Bs+LSIMF/26655901.html <p>TOKYO, Jun 17, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) today announced a strategic investment supported by the UK Government under the Life Sciences Innovative Manufacturing Fund (LSIMF), subject to terms and conditions, at its manufacturing site in Hatfield, Hertfordshire, United Kingdom, to establish supply chain and packaging capabilities for current and future medicines that require cold-chain management, including lecanemab.</p><p>LSIMF is a capital grants scheme designed to strengthen life sciences manufacturing capabilities in the UK and enhance supply resilience against future health emergencies. The investment aligns with the UK Government&apos;s policy http://www.streetinsider.com/Press+Releases/Eisai+Announces+Strategic+Investment+Supported+by+the+UK+Government%26apos%3Bs+LSIMF/26655901.html Tue, 16 Jun 2026 23:28:00 -0400 4523 A.50201142 ESAIY ESALF O.04940429 O.05105698 http://www.streetinsider.com/Press+Releases/Eisai+Announces+Strategic+Investment+Supported+by+the+UK+Government%26apos%3Bs+LSIMF/26655901.html <p>TOKYO, Jun 17, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) today announced a strategic investment supported by the UK Government under the Life Sciences Innovative Manufacturing Fund (LSIMF), subject to terms and conditions, at its manufacturing site in Hatfield, Hertfordshire, United Kingdom, to establish supply chain and packaging capabilities for current and future medicines that require cold-chain management, including lecanemab.</p><p>LSIMF is a capital grants scheme designed to strengthen life sciences manufacturing capabilities in the UK and enhance supply resilience against future health emergencies. The investment aligns with the UK Government&apos;s policy http://www.streetinsider.com/Press+Releases/Eisai+Announces+Strategic+Investment+Supported+by+the+UK+Government%26apos%3Bs+LSIMF/26655901.html Tue, 16 Jun 2026 23:28:00 -0400 4523 A.50201142 ESAIY ESALF O.04940429 O.05105698 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html <p>TOKYO, May 21, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;) announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), which is taking place in Chicago, Illinois and online from May 29 to June 2.</p><p>Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA(R)), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The http://www.streetinsider.com/Press+Releases/Eisai+Deepens+Body+of+Clinical+Evidence+for+LENVIMA%28R%29+%28Lenvatinib%29+Across+Established+Indications+at+ASCO+2026/26533889.html Thu, 21 May 2026 10:23:00 -0400 4523 A.11820776 A.31066700 A.37819586 A.50216726 ESAIY ESALF O.00000304 O.00093063 O.05105698 O.21612337 O.22422661 http://www.streetinsider.com/FDA/Merck+and+Eisai+report+failed+kidney+cancer+drug+trial+results/26340701.html <p>Merck & Co. (NYSE: MRK) and Eisai announced that their Phase 3 LITESPARK-012 trial evaluating combination treatments for advanced renal cell carcinoma did not meet its primary endpoints of progression-free survival and overall survival.</p> <p>The trial tested two experimental combination regimens against the established treatment of Keytruda plus Lenvima in 1,688 patients with advanced clear cell renal cell carcinoma. One combination included Keytruda, Lenvima, and Welireg, while the other tested MK-1308A plus Lenvima.</p> <p>At a pre-specified interim analysis, neither experimental combination demonstrated superior efficacy compared to the control arm of Keytruda plus Lenvima for first-line treatment. The companies reported that safety profiles http://www.streetinsider.com/FDA/Merck+and+Eisai+report+failed+kidney+cancer+drug+trial+results/26340701.html Tue, 21 Apr 2026 08:37:34 -0400 4523 A.06822034 A.11820776 A.41824856 ESAIY ESALF MRK O.00093063 O.03211432 O.05105698 O.20026344